Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381879 | 0.95 | HRH4 (0.50) | HRH4HTR3AHRH3KMT2AMAPT | |
| SCHEMBL2385612 | 0.85 | HRH4 (0.56) | HRH4HTR3AKMT2AMAPTTSHR | |
| SCHEMBL2385679 | 0.84 | HRH4 (0.61) | HRH4HTR3AHRH3 | |
| SCHEMBL2385881 | 0.81 | HRH4 (0.47) | HRH4HTR3AHRH3KMT2AMAPT | |
| SCHEMBL2384436 | 0.76 | HRH4 (0.74) | HRH4HTR3AHRH3MAPTHTT | |
| SCHEMBL2383521 | 0.76 | HRH4 (0.54) | HRH4HTR3AHRH3KMT2AMAPT | |
| SCHEMBL2385740 | 0.76 | HRH4 (0.51) | HRH4HTR3AHRH3MAPTHTT | |
| SCHEMBL2386809 | 0.75 | HRH4 (0.57) | HRH4HTR3AKMT2AMAPK1 | |
| SCHEMBL2382683 | 0.74 | HRH4 (0.76) | HRH4HTR3AKMT2AMAPTTSHR | |
| SCHEMBL4055646 | 0.73 | HRH4 (0.57) | HRH4HTR3AHRH3MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | claimed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | claimed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 14/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.